Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
ANCHOR study of time course of visual acuity changes: ranibizumab benefit stable over 2 years
Analysis of the time course of visual acuity outcomes during the first year of the ANCHOR study indicates that the mean visual acuity benefit of ranibizumab (Lucentis, Genentech) compared with photodynamic therapy (PDT) with verteporfin (Visudyne, Novartis) was observed after the first month of treatment, but that even patients who did not show this early benefit might respond later in the treatment course, said Jeffrey Heier, MD, Ophthalmic Consultants of Boston.
Related Videos
Related Content
